The power of pharmacological sciences: The example of proton pump inhibitors

Pharmacology

Volumn 76, Issue 3, 2006, Pages 148-155

  Spector, Reynold ^a,b   Vesell, Elliot S ^c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Drug development; Proton pump inhibitors; Stomach acid; Strategy for drug discovery

Indexed keywords

ANTACID AGENT; ANTIDEPRESSANT AGENT; CIMETIDINE; COLLOIDAL BISMUTH COMPOUND; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB; TRIPARANOL;

CLINICAL TRIAL; DIGESTIVE SYSTEM INFLAMMATION; DIGESTIVE SYSTEM ULCER; DRUG COST; DRUG RESEARCH; DRUG SAFETY; DRUG TOXICITY; DRUG USE; DUODENUM; DUODENUM ULCER; ENTEROCHROMAFFIN CELL; ESOPHAGITIS; ESOPHAGUS; ESOPHAGUS ULCER; GASTRECTOMY; GASTRITIS; GOVERNMENT; HEALTH CARE COST; HELICOBACTER INFECTION; HISTORY; HUMAN; HYPERGASTRINEMIA; HYPERPLASIA; MEDICARE; MEDICINE; NONHUMAN; PEPTIC ULCER; PHARMACOLOGICAL SCIENCE; PHILOSOPHY; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SCIENCE; STANDARD; STOMACH; STOMACH ACID; STOMACH ACID SECRETION; STOMACH ULCER; TUMOR; ULCER HEALING; UNITED STATES; VAGOTOMY;

DRUG COSTS; DRUG THERAPY; FORECASTING; GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMPS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33344464687     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091259     Document Type: Review

References (26)

1. Spector R: The Scientific Basis of Clinical Pharmacology: Principals and Examples. Boston, Little, Brown, 1986.
2. Spector R: Progress in the search for ideal drugs. Pharmacology 2002;64:1-7.
3. Davidoff F: The heartbreak of drug pricing. Ann Intern Med 2001;134:1068-1071.
4. Trudeau K: Natural Cures 'They' Don't Want You to Know About. New York, Alliance, 2005.
5. Spector R, Vesell ES: A rational approach to the selection of drugs for clinical practice. Pharmacology 2002;65:57-61.
6. Spector R, Vesell ES: Which studies of therapy merit credence? Vitamin E and estrogen as cautionary examples. J Clin Pharmacol 2002;42:955-962.
7. Woloshin S, Swartz LM, Tremmel J, Welch HG: Direct-to-consumer advertisements for prescription drugs: what are Americans being sold? Lancet 2001;358:1141-1146.
8. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calbins DR, Delbanco TL: Unconvention-al medicine in the United States - prevalence, costs, patterns of use. N Engl J Med 1993;328:246-252.
9. Olbe L, Carlsson E, Lindberg P: A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2:132-139.
10. Marshall B, Warren J: Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;i:1311-1313.
11. Altman LK: A Scientist gazing toward Stockholm, ponders 'what if?'. New York Times 2005;Dec 6:F5.
12. Martin DF, Hollanders D, May SJ, Ravenscroft MM, Tweedle Dt, Miller JP: Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1981;i:7-10.
13. Bombardier C, Laine L, Reicin A, Shapiro C, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
14. Haack S: Defending Science - Within Reason. Amherst, Prometheus, 2003.
15. Danto AC: Connections to the World. Berkeley, University of California Press, 1997.
16. Jenicek M: Foundations of Evidence-Based Medicine. Boca Raton, Parthenon, 2003.
17. Spector R, Vesell ES: The pursuit of truth: role of epidemiology/ observation studies. J Clin Pharmacol 2000;40:1205-1210.
18. Sosa E, Tooley M (eds): Causation. Oxford, Oxford University Press, 1993.
19. Kilcher P: The Advancement of Science. New York, Oxford University Press, 1993.
20. Scandinavian Simvistatin Survival Study Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvistatin Survival Study (4S). Lancet 1994;344:1383-1389.
21. Hoogerwerf WA, Pasricha PJ: Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease; in Brunton LL (ed): Goodman and Gilman's The Pharmacological Basis of Therapeutics, ed 11. New York, McGraw-Hill, 2005, pp 967-981.
22. Thomson ABR: Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole and rabeprazole. Curr Gastroenterol Rep 2000;2:482-483.
23. Dent J, Brun J, Fendrick AM, et al: An evidence-based appraisal of reflux disease management: the General Workshop Group. Gut 1999;44(suppl 2):S1-S16.
24. Scarpignato C, Pelosini J: Prevention and treatment of non-steroidal anti-inflammatory drug-induced gastro-duodenal damage: rationale for the use of antisecretory compounds. Ital J Gastroenterol Hepatol 1999;31(suppl 1):S63-S72.
25. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM: Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 2001;96:979-983.
26. Ofman JJ, Gralnek IM, Udani J, Fennerty MB, Fass R: The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999;107:219-227.